Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74

Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, Katheryn Lohith, Kexiang Xu, Kimberly J Edwards, Michael D Farwell, Carl H June, Steven M Albelda, Ellen Pure, Mark A Sellmyer Abstract Purpose: Despite the success of chimeric antigen [...]

August 18th, 2022|Publications|

Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types

Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra Abstract Background: The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [68Ga]Ga-FAPI-46 is a new radiotracer for in [...]

July 29th, 2022|Publications|

Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities

Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, Maria Lippert, Katharina Lueckerath, Lale Umutlu, Karina Kostbade, Ilektra A Mavroeidi, Martin Schuler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T Siveke, Rainer Hamacher Abstract Purpose: We [...]

July 14th, 2022|Publications|

Pitfalls and Common Findings in 68 Ga-FAPI PET: A Pictorial Analysis

Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Fadi Zarrad, Michael Nader, David Kersting, Manuel Weber, Sandra Kazek, Miriam Sraieb, Rainer Hamacher, Katharina Lueckerath, Lale Umutlu, Wolfgang P Fendler, Christoph Rischpler Abstract: Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of [...]

June 1st, 2022|Publications|

Comparison of 68 Ga-FAPI PET/CT and 18 FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement

Umut Elboga, Ertan Sahin, Tulay Kus, Yusuf Burak Cayirli, Gokmen Aktas, Merve Okuyan, Havva Yesil Cinkir, Fatih Teker, Ozlem Nuray Sever, Alper Aytekin, Latif Yılmaz, Aydın Aytekin, Ufuk Cimen, Vuslat Mumcu, Benan Kilbas, Kurtulus Eryilmaz, Davut Cakici, Yusuf Zeki Celen Purpose: In this study, we [...]

April 11th, 2022|Publications|

FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases

Torsten Kuwert, Christian Schmidkonz, Olaf Prante, Georg Schett, Andreas Ramming Abstract: In vivo visualization of inflammatory lesions in the body has been revolutionized by positron emission tomography (PET) with F-18-deoxyglucose (FDG) as a tracer and by magnetic resonance imaging (MRI) with gadolinium-labelled contrast media. Apart [...]

April 7th, 2022|Publications|

Comparison of 68 Ga-FAPI and 18 F-FDG PET/CT in the Evaluation of Advanced Lung Cancer

Lijuan Wang, Ganghua Tang, Kongzhen Hu, Xinran Liu, Wenlan Zhou, Hongsheng Li, Shun Huang, Yanjiang Han, Li Chen, Jinmei Zhong, Hubing WuAbstract:Background Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor (FAPI) has recently been introduced as a promising tumor imaging agent. Purpose To compare 68Ga-FAPI PET/CT with fluorine [...]

April 1st, 2022|Publications|

Head-to-head Intra-individual Comparison of [ 68 Ga]-FAPI and [ 18 F]-FDG PET/CT in Patients with Bladder Cancer

E Novruzov, K Dendl, H Ndlovu, P L Choyke, M Dabir, M Beu, F Novruzov, E Mehdi, F Guliyev, S A Koerber, I Lawal, G Niegisch, J Debus, U Haberkorn, M Sathekge, F L Giesel Aim/purpose: Fibroblast activation protein-(FAP)-ligands, a novel class of tracers for [...]

March 29th, 2022|Publications|

Feasibility of [ 68 Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

Lena M Unterrainer, Simon Lindner, Lennert Eismann, Jozefina Casuscelli, Franz-Josef Gildehaus, Vinh Ngoc Bui, Nathalie L Albert, Adrien Holzgreve, Leonie Beyer, Andrei Todica, Matthias Brendel, Clemens C Cyran, Alexander Karl, Christian G Stief, Stephan T Ledderose, Marcus Unterrainer, Peter Bartenstein, Vera Wenter, Alexander Kretschmer [...]

March 24th, 2022|Publications|

Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, Pinar Cakmak, Karl-Heinz Plate, Gabriela Kramer-Marek Abstract: Cancer-associated fibroblasts (CAFs) can strongly modulate the response to therapy of malignant tumor cells, facilitating their continuous proliferation and invading behaviors. In this context, several [...]

February 22nd, 2022|Publications|


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top